Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy

Written By Noah Davidsohn
Noah Davidsohn
Previous

Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis
Next

New Preclinical Research Evaluating Cellular Reprogramming for Age Reversal